Vertex Ventures HC

Vertex Ventures HC is a venture capital firm established in 2013 and based in San Francisco, California. The firm specializes in investing across various sectors of the healthcare industry, including biopharmaceuticals, medical devices, and digital health. It targets companies at different stages of development, from early-stage firms exploring innovative technologies to established companies aiming for further growth. Vertex Ventures HC focuses on addressing significant unmet needs in healthcare, with the goal of building companies that enhance health and quality of life. The firm actively engages with its portfolio companies, collaborating with skilled entrepreneurs, industry partners, and other investors to drive value creation. Its team comprises investment professionals with extensive expertise in scientific, medical, and business fields, ensuring informed decision-making in their investment strategy.

Amanda Chen

Senior Associate

Lori Hu

Managing Director

David Meter

Venture Partner

41 past transactions

Indapta Therapeutics

Venture Round in 2024
Indapta Therapeutics is a privately held biotechnology company that focuses on the development of a natural killer (NK) cell therapy platform aimed at treating various blood and solid tumor cancers. The company specializes in commercializing a proprietary, off-the-shelf, non-engineered, and allogeneic G-NK cell designed to enhance the immune response and significantly improve the cytotoxicity of antibody therapies. By harnessing the potent antibody-dependent cellular cytotoxicity (ADCC) activity of these NK cells, Indapta Therapeutics enables healthcare providers to offer innovative treatment options for patients battling cancer.

Moximed

Series D in 2024
Moximed, Inc. is a medical technology company based in Hayward, California, that focuses on developing innovative treatments for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain associated with medial compartment knee osteoarthritis, allowing patients to maintain high levels of activity. Additionally, Moximed has developed the MISHA Knee System, which provides an outpatient treatment option for individuals who have not responded to conventional therapies and are not suitable candidates for knee replacement surgery. By minimizing joint pain and providing dynamic load reduction, Moximed's implants aim to improve the standard of care and enhance the quality of life for patients, potentially delaying or avoiding the need for more invasive surgical interventions. Moximed has been operational since its incorporation in 2006, serving patients and medical professionals globally.

NeuSpera Medical

Series D in 2024
NeuSpera Medical Inc. is a company based in San Jose, California, that specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy. Established in 2013, NeuSpera Medical utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to transmit energy, allowing for external powering of its implants. This innovative approach facilitates minimally invasive interventions aimed at treating chronic conditions such as Urinary Urgency Incontinence and chronic peripheral nerve pain. The company's focus on bioelectronic medicine positions it as a key player in advancing therapeutic solutions through its cutting-edge implantable technology.

TORL BioTherapeutics

Series B in 2024
TORL BioTherapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, antibody-based therapies aimed at enhancing the lives of cancer patients. The company specializes in antibody-drug conjugates and other biologics, focusing on oncologic diseases with significant unmet medical needs. TORL BioTherapeutics employs a strategy that involves target identification and early discovery work, allowing them to selectively advance drug programs through novel licensing agreements. This approach enables their researchers to develop proprietary drugs with unique and optimized profiles, contributing to the advancement of cancer treatment options.

Eyebiotech

Series A in 2023
Eyebiotech is a vision treatment company that develops products to preserve, repair, and improve eyesight. The firm guards against sight-threatening eye disorders and developed the first anti-vascular endothelial growth factor medication for patients with age-related macular degeneration, allowing those with eye ailments to regain their eyesight.

Septerna

Series B in 2023
Septerna is a biotechnology company focused on the discovery and development of novel small-molecule medicines that target G protein-coupled receptors (GPCRs). The company aims to improve patient outcomes by leveraging advanced drug discovery technologies, including innovative screening methods and structure-based drug design. Septerna utilizes its proprietary Native Complex platform to facilitate industrial-scale drug discovery, enabling researchers to identify effective treatments for a diverse array of diseases. Through its commitment to combining cutting-edge technology with a focus on GPCR targets, Septerna seeks to advance the field of medicine and enhance the quality of life for patients.

SpyGlass Pharma

Series C in 2023
SpyGlass Pharma specializes in developing innovative treatments for chronic ophthalmic diseases through advanced technology. The company creates ophthalmic devices and a drug delivery platform aimed at enhancing vision and eye care for patients. Its products address unmet needs in areas such as cataracts, lens replacement, and surgical procedures. The drug delivery platform is designed to be implanted alongside intraocular lenses during standard cataract surgeries, allowing for the provision of multi-year therapy to treat chronic eye conditions. This approach not only facilitates effective treatment but also aims to make quality eye care more accessible and affordable for patients.

Boundless Bio

Series C in 2023
Boundless Bio, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, focused on developing innovative therapies for the treatment of aggressive cancers. The company specializes in targeting extrachromosomal DNA (ecDNA), a key factor in the amplification of oncogenes that affects over 14% of cancer patients. By investigating the biology of ecDNA, Boundless Bio aims to create transformative treatments for previously untreatable cancers. Its lead therapeutic candidate, BBI-355, is an oral selective inhibitor of checkpoint kinase 1 (CHK1) designed to manage the replication and transcription of ecDNA in cancer cells. Founded in 2018, Boundless Bio is committed to addressing the significant unmet medical needs of patients with oncogene amplified tumors.

TORL BioTherapeutics

Series B in 2023
TORL BioTherapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, antibody-based therapies aimed at enhancing the lives of cancer patients. The company specializes in antibody-drug conjugates and other biologics, focusing on oncologic diseases with significant unmet medical needs. TORL BioTherapeutics employs a strategy that involves target identification and early discovery work, allowing them to selectively advance drug programs through novel licensing agreements. This approach enables their researchers to develop proprietary drugs with unique and optimized profiles, contributing to the advancement of cancer treatment options.

SonoThera

Series A in 2022
SonoThera is a biotechnology company focused on developing innovative genetic therapies using ultrasound technology. The company's mission is to create non-viral genetic medicines that address the root causes of human diseases. SonoThera specializes in ultrasound-guided nonviral gene therapy, aiming to provide effective treatments for conditions that currently have suboptimal or no available treatments. By leveraging this approach, SonoThera seeks to enhance the health and quality of life for millions of people worldwide.

Matchpoint Therapeutics

Series A in 2022
Matchpoint Therapeutics is a biotechnology company focused on developing precision covalent medicines aimed at transforming the treatment of immune diseases and other serious illnesses. Utilizing its proprietary Advanced Covalent Exploration (ACE) platform, the company combines advanced chemoproteomics, machine learning, and the evolution of covalent chemistry libraries to enhance the discovery process. This innovative approach allows for deeper probing of the proteome to identify new binding sites on disease-causing proteins. Matchpoint is building an emerging pipeline of novel covalent medicines, with an initial emphasis on immunology.

Allay Therapeutics

Series C in 2021
Allay Therapeutics is focused on developing innovative solutions for post-surgical pain management, aiming to enhance patient recovery experiences. The company utilizes a proprietary technology platform that integrates validated non-opioid analgesics with biopolymers to create dissolvable therapeutics. These products are designed to deliver targeted pain relief over extended periods, significantly surpassing the duration of existing pain treatments. Allay's lead investigational product, ATX101, is currently undergoing evaluation in a Phase 2 clinical study for total knee arthroplasty surgeries. With a diverse team of entrepreneurs, scientists, and clinicians based in the San Francisco Bay Area and Singapore, Allay Therapeutics seeks to address the limitations of conventional pain management approaches, particularly the challenges associated with opioid use.

Obsidian Therapeutics

Series B in 2021
Obsidian Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing next-generation cell and gene therapies aimed at enhancing adoptive immunotherapy for cancer patients. Its innovative approach utilizes pharmacologic operating systems that enable precise control over protein activity within cells. This technology allows for the creation of adoptive cell therapies with novel functionalities, which can be regulated by treating physicians using simple and safe orally active medications. Through these advancements, Obsidian Therapeutics seeks to improve upon existing cell therapies and expand treatment options for a broader patient demographic.

Sonoma Biotherapeutics

Series B in 2021
Sonoma Biotherapeutics, Inc. is focused on developing adoptive T regulatory (Treg) cell therapies aimed at treating autoimmune and degenerative diseases. Established in 2019 and based in South San Francisco, California, with an additional office in Seattle, the company employs next-generation genome editing and target-specific cell therapy techniques to innovate in the field of Treg cell therapeutics. The firm aims to create disease-modifying and potentially curative therapies that promote self-tolerance and inhibit harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded by experts in Treg biology and cell therapy, Sonoma Biotherapeutics integrates advanced methodologies to enhance its therapeutic offerings.

NeuSpera Medical

Series C in 2021
NeuSpera Medical Inc. is a company based in San Jose, California, that specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy. Established in 2013, NeuSpera Medical utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to transmit energy, allowing for external powering of its implants. This innovative approach facilitates minimally invasive interventions aimed at treating chronic conditions such as Urinary Urgency Incontinence and chronic peripheral nerve pain. The company's focus on bioelectronic medicine positions it as a key player in advancing therapeutic solutions through its cutting-edge implantable technology.

Boundless Bio

Series B in 2021
Boundless Bio, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, focused on developing innovative therapies for the treatment of aggressive cancers. The company specializes in targeting extrachromosomal DNA (ecDNA), a key factor in the amplification of oncogenes that affects over 14% of cancer patients. By investigating the biology of ecDNA, Boundless Bio aims to create transformative treatments for previously untreatable cancers. Its lead therapeutic candidate, BBI-355, is an oral selective inhibitor of checkpoint kinase 1 (CHK1) designed to manage the replication and transcription of ecDNA in cancer cells. Founded in 2018, Boundless Bio is committed to addressing the significant unmet medical needs of patients with oncogene amplified tumors.

Elevation Oncology

Series B in 2020
Elevation Oncology, Inc. is a biotechnology company dedicated to creating precision medicines for patients with genomically defined cancers. Founded in 2019 and headquartered in New York, it specializes in developing targeted therapeutics that inhibit specific genetic alterations known to drive cancer progression. The company's lead candidate, seribantumab, aims to address tumors associated with NRG1 fusions, which are rare genomic changes that can be effectively targeted through HER3 inhibition. Currently, seribantumab is undergoing clinical evaluation in the Phase 2 CRESTONE study, which focuses on patients with tumors of any origin exhibiting NRG1 fusions. Elevation Oncology is committed to making genomic testing actionable by advancing innovative treatments tailored to the unique genetic profiles of cancer patients.

Palleon Pharmaceuticals

Series B in 2020
Palleon Pharmaceuticals Inc. is a biotechnology company dedicated to developing innovative therapeutics that target glycan-mediated immune regulation for the treatment of cancer and inflammatory diseases. Founded in 2015 and based in Waltham, Massachusetts, the company specializes in glycoimmune checkpoint inhibitors, leveraging advanced insights from glycoscience and human immunology. Palleon's biotechnology platform aims to provide a novel approach to cancer treatment by targeting various immune cell types, thus offering physicians an expanded array of combination therapies to enhance treatment efficacy and address resistance to existing immuno-oncology agents. In addition to cancer, the company also focuses on therapeutics for inflammatory diseases, including autoimmunity and fibrosis.

Elevation Oncology

Series A in 2020
Elevation Oncology, Inc. is a biotechnology company dedicated to creating precision medicines for patients with genomically defined cancers. Founded in 2019 and headquartered in New York, it specializes in developing targeted therapeutics that inhibit specific genetic alterations known to drive cancer progression. The company's lead candidate, seribantumab, aims to address tumors associated with NRG1 fusions, which are rare genomic changes that can be effectively targeted through HER3 inhibition. Currently, seribantumab is undergoing clinical evaluation in the Phase 2 CRESTONE study, which focuses on patients with tumors of any origin exhibiting NRG1 fusions. Elevation Oncology is committed to making genomic testing actionable by advancing innovative treatments tailored to the unique genetic profiles of cancer patients.

Epirium Bio

Series A in 2019
Epirium Bio, Inc. is a biopharmaceutical company based in San Diego, California, focused on developing therapeutics for cardiovascular diseases, metabolic syndrome, and disorders characterized by mitochondrial dysfunction. Founded in 2008, the company leverages unique insights into mitochondrial biology and tissue regeneration to create a small molecule platform aimed at improving muscle strength and facilitating tissue regeneration. Epirium Bio's innovative approach addresses significant clinical needs in treating neuromuscular, neurodegenerative, and mitochondrial disorders, enabling healthcare providers to better support patients suffering from conditions such as muscular dystrophy.

Blackthorn Therapeutics

Series B in 2019
Blackthorn Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, founded in 2013. The company focuses on developing precision medicine for neurobehavioral disorders, utilizing advances in computational and clinical neuroscience. By leveraging its proprietary computational platform, Blackthorn aims to address historical challenges in drug discovery by targeting dysfunctional brain circuits. This approach enables the identification of novel drug candidates and biologically-based patient subgroups that are most likely to respond to specific treatments. Through its innovative strategies, Blackthorn seeks to enhance the precision of therapeutic interventions for disorders of the central nervous system, ultimately improving patient outcomes.

Twentyeight-Seven Therapeutics

Series A in 2019
Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.

Nuvaira

Series E in 2019
Nuvaira, Inc. is a medical device company based in Minneapolis, Minnesota, focused on developing innovative treatments for obstructive lung diseases, particularly chronic obstructive pulmonary disease (COPD). Founded in 2008, Nuvaira specializes in a novel catheter-based Lung Denervation System that aims to address airway nerve hyperactivity by targeting the parasympathetic innervation of the lungs. This minimally invasive procedure is designed to improve lung function, enhance exercise capacity, and elevate the quality of life for patients suffering from chronic respiratory conditions. With a commitment to advancing treatment options, Nuvaira seeks to reduce the clinical consequences associated with neural hyperactivity in conditions such as COPD and asthma.

EarLens

Series D in 2018
EarLens is a privately held medical technology company focused on enhancing the hearing experience for individuals with hearing loss. The firm has pioneered the Earlens Contact Hearing Solution, a groundbreaking device that directly activates the natural hearing process. This innovative system utilizes low-frequency radio signals and a small lens placed on the eardrum to vibrate it, allowing for superior sound quality and a broader bandwidth than traditional hearing aids. Unlike conventional devices that amplify sound, the Earlens solution delivers sound directly to the eardrum, thereby minimizing feedback and ensuring clear hearing in various environments. The second generation of this technology received FDA clearance in 2019, marking a significant advancement in the standard of care for hearing performance.

Twentyeight-Seven Therapeutics

Series A in 2018
Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.

Bicycle Therapeutics

Series B in 2018
Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, specializing in the development of a novel class of medicines known as Bicycles. These are synthetic short peptides designed to form two loops that stabilize their structure. The company's lead product candidate, BT1718, is a Bicycle Toxin Conjugate (BTC) currently undergoing Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also a BTC in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies targeting Nectin-4. Additionally, Bicycle is advancing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to address therapeutic areas such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. Bicycle Therapeutics was incorporated in 2009 and aims to address significant unmet medical needs in oncology and beyond.

Obsidian Therapeutics

Series A in 2017
Obsidian Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing next-generation cell and gene therapies aimed at enhancing adoptive immunotherapy for cancer patients. Its innovative approach utilizes pharmacologic operating systems that enable precise control over protein activity within cells. This technology allows for the creation of adoptive cell therapies with novel functionalities, which can be regulated by treating physicians using simple and safe orally active medications. Through these advancements, Obsidian Therapeutics seeks to improve upon existing cell therapies and expand treatment options for a broader patient demographic.

Visterra

Series C in 2017
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based therapies for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra creates novel biological medicines targeting a range of conditions. Its product pipeline includes VIS410, a monoclonal antibody aimed at all known strains of influenza A, VIS513 for Dengue treatment, VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649 for Immunoglobulin A Nephropathy. Founded in 2007 and originally named Parasol Therapeutics, Inc., the company rebranded to Visterra in April 2010 and is headquartered in Waltham, Massachusetts. As of August 2018, Visterra operates as a subsidiary of Otsuka America, Inc.

Palleon Pharmaceuticals

Series A in 2017
Palleon Pharmaceuticals Inc. is a biotechnology company dedicated to developing innovative therapeutics that target glycan-mediated immune regulation for the treatment of cancer and inflammatory diseases. Founded in 2015 and based in Waltham, Massachusetts, the company specializes in glycoimmune checkpoint inhibitors, leveraging advanced insights from glycoscience and human immunology. Palleon's biotechnology platform aims to provide a novel approach to cancer treatment by targeting various immune cell types, thus offering physicians an expanded array of combination therapies to enhance treatment efficacy and address resistance to existing immuno-oncology agents. In addition to cancer, the company also focuses on therapeutics for inflammatory diseases, including autoimmunity and fibrosis.

EarLens

Series C in 2017
EarLens is a privately held medical technology company focused on enhancing the hearing experience for individuals with hearing loss. The firm has pioneered the Earlens Contact Hearing Solution, a groundbreaking device that directly activates the natural hearing process. This innovative system utilizes low-frequency radio signals and a small lens placed on the eardrum to vibrate it, allowing for superior sound quality and a broader bandwidth than traditional hearing aids. Unlike conventional devices that amplify sound, the Earlens solution delivers sound directly to the eardrum, thereby minimizing feedback and ensuring clear hearing in various environments. The second generation of this technology received FDA clearance in 2019, marking a significant advancement in the standard of care for hearing performance.

Moximed

Series C in 2017
Moximed, Inc. is a medical technology company based in Hayward, California, that focuses on developing innovative treatments for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain associated with medial compartment knee osteoarthritis, allowing patients to maintain high levels of activity. Additionally, Moximed has developed the MISHA Knee System, which provides an outpatient treatment option for individuals who have not responded to conventional therapies and are not suitable candidates for knee replacement surgery. By minimizing joint pain and providing dynamic load reduction, Moximed's implants aim to improve the standard of care and enhance the quality of life for patients, potentially delaying or avoiding the need for more invasive surgical interventions. Moximed has been operational since its incorporation in 2006, serving patients and medical professionals globally.

Innoventure

Series A in 2016
Innoventure is a startup medical device accelerator which brings US/EU medtech assets to China and get through the local regulatory path to develop further value.

EarLens

Series C in 2016
EarLens is a privately held medical technology company focused on enhancing the hearing experience for individuals with hearing loss. The firm has pioneered the Earlens Contact Hearing Solution, a groundbreaking device that directly activates the natural hearing process. This innovative system utilizes low-frequency radio signals and a small lens placed on the eardrum to vibrate it, allowing for superior sound quality and a broader bandwidth than traditional hearing aids. Unlike conventional devices that amplify sound, the Earlens solution delivers sound directly to the eardrum, thereby minimizing feedback and ensuring clear hearing in various environments. The second generation of this technology received FDA clearance in 2019, marking a significant advancement in the standard of care for hearing performance.

Visterra

Series C in 2016
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based therapies for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra creates novel biological medicines targeting a range of conditions. Its product pipeline includes VIS410, a monoclonal antibody aimed at all known strains of influenza A, VIS513 for Dengue treatment, VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649 for Immunoglobulin A Nephropathy. Founded in 2007 and originally named Parasol Therapeutics, Inc., the company rebranded to Visterra in April 2010 and is headquartered in Waltham, Massachusetts. As of August 2018, Visterra operates as a subsidiary of Otsuka America, Inc.

Kona Medical

Debt Financing in 2015
Kona Medical, Inc. is a medical technology company that specializes in developing a non-invasive ultrasound-based therapy system aimed at treating hypertension and related disorders. Established in 2009 by Dr. Michael Gertner, the company focuses on addressing the challenges posed by drug-resistant hypertension through innovative approaches, particularly renal artery denervation. Its flagship product, Surround Sound, employs ultrasound imaging to precisely guide the delivery of focused ultrasound energy for renal denervation, offering a less invasive alternative to traditional treatments. Based in Issaquah, Washington, Kona Medical integrates Dr. Gertner's inventions with assets from Therus Corporation, enhancing its capabilities in therapeutic focused ultrasound.

Moximed

Series B in 2015
Moximed, Inc. is a medical technology company based in Hayward, California, that focuses on developing innovative treatments for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain associated with medial compartment knee osteoarthritis, allowing patients to maintain high levels of activity. Additionally, Moximed has developed the MISHA Knee System, which provides an outpatient treatment option for individuals who have not responded to conventional therapies and are not suitable candidates for knee replacement surgery. By minimizing joint pain and providing dynamic load reduction, Moximed's implants aim to improve the standard of care and enhance the quality of life for patients, potentially delaying or avoiding the need for more invasive surgical interventions. Moximed has been operational since its incorporation in 2006, serving patients and medical professionals globally.

Twelve

Series C in 2015
Twelve manufactures medical devices. It was formerly known as Foundry Newco XII, Inc. The company was incorporated in 2009 and is based in Menlo Park, California.

Visterra

Series B in 2014
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based therapies for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra creates novel biological medicines targeting a range of conditions. Its product pipeline includes VIS410, a monoclonal antibody aimed at all known strains of influenza A, VIS513 for Dengue treatment, VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649 for Immunoglobulin A Nephropathy. Founded in 2007 and originally named Parasol Therapeutics, Inc., the company rebranded to Visterra in April 2010 and is headquartered in Waltham, Massachusetts. As of August 2018, Visterra operates as a subsidiary of Otsuka America, Inc.

Ivantis

Series B in 2014
Ivantis Inc. is a medical device company based in Irvine, California, focused on developing innovative treatments for primary open-angle glaucoma. Founded in 2007, the company has created a minimally invasive intracanalicular scaffold that helps alleviate high intraocular pressure by restoring the natural drainage pathway in Schlemm's canal. This device aims to provide a less invasive and more effective solution for the over 60 million individuals worldwide affected by this condition. In addition to its glaucoma treatments, Ivantis plans to expand its research and development efforts to address other challenging diseases within the field of ophthalmology. The company's products are utilized in clinical trials by ophthalmology specialists across the United States.

Nuvaira

Series D in 2014
Nuvaira, Inc. is a medical device company based in Minneapolis, Minnesota, focused on developing innovative treatments for obstructive lung diseases, particularly chronic obstructive pulmonary disease (COPD). Founded in 2008, Nuvaira specializes in a novel catheter-based Lung Denervation System that aims to address airway nerve hyperactivity by targeting the parasympathetic innervation of the lungs. This minimally invasive procedure is designed to improve lung function, enhance exercise capacity, and elevate the quality of life for patients suffering from chronic respiratory conditions. With a commitment to advancing treatment options, Nuvaira seeks to reduce the clinical consequences associated with neural hyperactivity in conditions such as COPD and asthma.

SENSIMED

Series C in 2013
Sensimed AG is a medical devices company based in Lausanne, Switzerland, founded in 2003. The company specializes in the design, development, and commercialization of integrated micro-systems for medical applications, particularly focusing on glaucoma management. Its flagship product, the SENSIMED Triggerfish, is a soft, single-use contact lens that enables continuous monitoring of intraocular pressure (IOP) fluctuations in glaucoma patients over a 24-hour period. The Triggerfish system includes disposable sensors, an adhesive antenna for communication, a battery-powered recorder for data collection, and software for data management and analysis. Sensimed aims to enhance personalized treatment for glaucoma patients by analyzing the collected data to identify pathological patterns and improve clinical outcomes. The company's products are distributed through partners across Europe, Asia-Pacific, the Middle East, and the Americas. As of December 2019, Sensimed operates as a subsidiary of SEED Co., Ltd.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.